Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2013

View Archived Issues

First-in-human study results of ISIS-SMNRx in children with spinal muscular atrophy

Spanish researchers develop new combinatorial drug delivery and neuronal activity recording probe

Ohr Pharmaceutical reports results from phase II trial of OHR/AVR-118 in cancer cachexia

Potential benefit demonstrated for tamoxifen in mouse model of DMD

FDA and EMA set to review Piramal Imaging's marketing applications

Threshold set to acquire Siemen's investigational hypoxia PET imaging agent

SD-809 demonstrates improved pharmacokinetic profile in healthy volunteers

BIO5-TGen forms collaboration focused on drug development for Alzheimer's disease

Photochemical internalization of bleomycin using TPCS2a

Biotest to begin phase IIb trial of tregalizumab in rheumatoid arthritis

Parent Project Muscular Dystrophy funds research for potential new DMD treatment

RaQualia and Carna Biosciences form drug discovery collaboration

Implantation of encapsulated NGF-releasing cells safe and well tolerated in patients with AD

CHMP recommends approval of rivaroxaban in new indication

CHMP recommends against E.U. approval of Gentium's defibrotide

European CHMP recommends restriction on use of cilostazol-based medicines

Intrathecal idursulfase proves effective in children with Hunter's syndrome

Viamet Pharmaceuticals discloses new cytochrome P450 inhibitors

IRM discloses novel protein kinase inhibitors

Roche prepares new JAK3/SYK protein kinase inhibitors

Merz Pharma presents novel glycine B receptor antagonists

Arzerra approved in Japan

FDA denies approval of oral treprostinil in PAH

Regorafenib approved in Japan for colorectal cancer

NDA submitted for empagliflozin in type 2 diabetes

Xeljanz obtains approval in Japan for rheumatoid arthritis

MST-188 obtains orphan drug designation in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...